Supreme Court Declines to Opine on Circuit Split Over Rule 9(b) Pleading Requirements for FCA Claims

Published date07 June 2014
Law FirmEpstein Becker & Green
AuthorGeorge Breen,Amy Dow,Daniel C. Fundakowski,Lynn Shapiro Snyder
Subject MatterCertiorari,Dismissals,False Claims Act (FCA),Healthcare Fraud,Medicare,Off-Label Use,Pharmaceutical Industry,Pleading Standards,Popular,Qui Tam,Rule 9(b),SCOTUS,Split of Authority,Takeda Pharmaceuticals,Whistleblowers

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT